Exenatide Delays the Progression of Nonalcoholic Fatty Liver Disease in C57BL/6 Mice, Which May Involve Inhibition of the NLRP3 Inflammasome through the Mitophagy Pathway

Figure 1

Effect of Exe on reducing body and liver weight and relieving hepatic lipid accumulation after four weeks of treatment: (a) body weight; (b) ratio of liver weight to body weight; (c) liver size; (d) representative photographs (400x) of H&E-stained liver sections. Liver TC (e) and TG (f) levels were determined. Data are expressed as (n = 7-8). , model versus control group; and , Exe versus model group. Exe: exenatide; TC: total cholesterol; TG: triglyceride.

(a)

(b)

(c)

(d)

(e)

(f)